Faculty, Staff and Student Publications
Publication Date
10-1-2022
Journal
Lancet Oncology
Abstract
BACKGROUND: Systemic corticosteroids are commonly prescribed for palliation of dyspnoea in patients with cancer, despite scarce evidence to support their use. We aimed to assess the effect of high-dose dexamethasone versus placebo on cancer-related dyspnoea.
METHODS: This double-blind, multi-site, parallel group randomized trial enrolled ambulatory patients with cancer, age ≥18, average dyspnea intensity over the past week ≥4/10 in a 0–10 point numeric rating scale and randomly assigned them to receive dexamethasone 8 mg orally every 12 hours for 7 days followed by 4 mg orally every 12 hours for 7 days or matching placebo capsules. Pharmacists conducted permuted block randomization (block size=6, 2:1) stratified by baseline dyspnea and study site. Patients, research staff and clinicians were blinded. The primary outcome was change in dyspnea intensity assessed with a 0–10 numeric rating scale (0=none, 10=worst) between baseline and day 7. Comparisons between groups were done by modified intention-totreat analysis. This study is registered with ClinicalTrials.gov, NCT03367156. Enrollment was stopped after second pre-planned interim analysis when futility criterion was met.
FINDINGS: Between Jan 11, 2018, and April 23, 2021, we screened 2867 patients, enrolled 149 patients, and randomly assigned 128 to dexamethasone (n=85) or placebo (n=43). The mean change in dyspnoea NRS intensity from baseline to day 7 (±2 days) was -1·6 (95% CI -2·0 to -1·2) in the dexamethasone group and -1·6 (-2·3 to -0·9) in the placebo group, with no significant between-group difference (mean 0 [95% CI -0·8 to 0·7]; p=0·48). The most common all-cause grade 3-4 adverse events were infections (nine [11%] of 85 patients in the dexamethasone group vs three [7%] of 43 in the placebo group), insomnia (seven [8%] vs one [2%]), and neuropsychiatric symptoms (three [4%] vs none [0%]). Serious adverse events, all resulting in hospital admissions, were reported in 24 (28%) of 85 patients in the dexamethasone group and in three (7%) of 43 patients in the placebo group. No treatment-related deaths occurred in either group.
INTERPRETATION: High-dose dexamethasone did not improve dyspnoea in patients with cancer more effectively than placebo and was associated with a higher frequency of adverse events. These data suggest that dexamethasone should not be routinely given to unselected patients with cancer for palliation of dyspnoea.
FUNDING: US National Cancer Institute.
Keywords
Adrenal Cortex Hormones, Dexamethasone, Double-Blind Method, Dyspnea, Humans, Neoplasms, Treatment Outcome, Corticosteroids, dyspnea, neoplasms, pharmacologic therapy, palliative care, randomized controlled trial
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons
Comments
Supplementary Materials
PMID: 36087590